RDY

Business Context and Reporting Period

Company: Dr. Reddy's Laboratories Limited (DRL)
Filing Type: Form 6-K (Quarterly Report)
Reporting Period: Three months ended June 30, 2015
Currency: Indian Rupees (Rs.) with U.S. Dollar (U.S.$) convenience translation at Rs.63.59 = U.S.$1.00

DRL is a leading India-based pharmaceutical company operating through three primary segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The company manufactures and markets active pharmaceutical ingredients (APIs), generic formulations, and proprietary products globally, with significant operations in the United States, India, Russia, and Europe.

Key Financial Metrics

Note: Total Borrowings calculated as Short-term (Rs.22,221) + Long-term (Rs.19,179).

Material Changes vs. Prior Period

• Revenue Growth: Consolidated revenues increased 7% to Rs.37,578 million, driven primarily by an 8% increase in the Global Generics segment.
• Profitability: Net profit rose 14% to Rs.6,257 million. Gross margin expanded to 61.1% from 59.3% due to higher realizations from new products and a favorable business mix.
• Segment Performance:
  • Global Generics: Revenues grew 8%. North America revenues increased 14% (9% in constant currency) due to new product launches (e.g., valganciclovir, Habitrol) and market share gains. Russia revenues declined 45% (22% in constant currency) due to macroeconomic conditions.
  • PSAI: Revenues grew 1%, with increased pharmaceutical development services offsetting lower API sales volumes.
  • Proprietary Products: Revenues grew 22%.
• Acquisition: Completed the acquisition of a select portfolio of products from UCB India on June 16, 2015, for a total consideration of Rs.8,000 million. This added Rs.60 million in revenue for the quarter.
• Finance Costs: Net finance income decreased 55% to Rs.216 million, primarily due to a shift from a net foreign exchange gain of Rs.476 million in the prior year to a net loss of Rs.88 million in the current quarter, largely driven by Venezuela operations.

Guidance, Outlook, Risks, and Unusual Items

• Outlook & Strategy: Management continues to focus on expanding R&D in complex formulations and biosimilars. R&D expenses increased 13% to Rs.4,387 million (11.7% of revenue). The company is actively pursuing new ANDA filings (225 cumulative filings as of June 30, 2015).
• Collaborations:
  • Curis, Inc.: Entered a collaboration for immuno-oncology; received equity shares valued at Rs.1,452 million as upfront consideration.
  • Amgen: Subsequent to the period end (August 6, 2015), entered an agreement to market three Amgen medicines in India.
• Risks & Contingencies:
  • Venezuela Operations: Significant foreign exchange risk due to a multi-tiered currency regime. The company recorded a foreign exchange loss of Rs.99 million on translation of monetary assets/liabilities using the SIMADI rate.
  • Legal Proceedings: Ongoing litigation includes antitrust class actions regarding Nexium and Namenda settlements (Company maintains conduct was compliant), patent infringement suits regarding Reclast and Zometa, and regulatory investigations by the CPSC regarding child-resistant packaging.
  • Regulatory/Tax: Pending disputes regarding input service tax credits, VAT, and fuel surcharge adjustments in India. The company believes the probability of material liability for most of these is not probable.
• Unusual Items: Inventory write-downs were Rs.489 million. The company recorded a gain of Rs.1,012 million in Other Comprehensive Income related to the fair value change of Curis equity shares.

Investor Verification Checklist

• Venezuela Exposure: Verify the impact of the SIMADI exchange rate on future earnings and the realizability of cash balances in Venezuela (Rs.2,113 million restricted).
• Acquisition Integration: Assess the revenue contribution and integration costs of the UCB portfolio acquisition.
• Legal Liabilities: Monitor the status of the Nexium, Namenda, and Reclast/Zometa litigation for potential settlement costs or injunctions.
• Working Capital: Review the increase in Days Sales Outstanding (DSO) to 101 days, attributed to longer credit periods in the U.S. market.
• Debt Profile: Confirm compliance with financial covenants on the U.S.$220 million Swiss subsidiary loan and U.S.$150 million parent company loan.